Ask AI
ProCE Banner Activity

Perspective européenne sur les approches actuelles visant à optimiser les soins aux patients atteints de lymphome à cellules du manteau (LCM)

Clinical Thought

Dans ce commentaire, un expert aborde le rôle croissant des inhibiteurs de BTK et des traitements sans chimiothérapie dans la prise en charge des patients atteints de LCM, ainsi que l’importance de gérer de manière proactive les effets indésirables liés au traitement afin de prolonger la durée du traitement et d’améliorer les résultats cliniques et la qualité de vie.

Released: February 24, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan BTK inhibitor-based combination strategies for patients with treatment-naïve MCL, considering new indications, expert recommendations, and available efficacy and safety evidence

  • Select chemotherapy-free treatment strategies for appropriate patients with MCL

  • Manage treatment-related adverse events associated with targeted therapies alone or in combination to extend duration on treatment and improve clinical outcomes

Disclosure

Primary Author

Mats Jerkeman, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Kite/Gilead, Lilly, Roche.